Publication | Open Access
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
37
Citations
32
References
2022
Year
Our study confirms in a large and global population of patients with advanced HCC, not candidates for locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib.
| Year | Citations | |
|---|---|---|
Page 1
Page 1